Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer - Concepedia

Concepedia

Publication | Open Access

Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

DOI Full Paper Access

85

Citations

35

References

2021

Year

Dong Ding, Huabin Hu, Shuosha Li, Youwen Zhu, Shi Yin, Mengting Liao, Jin Liu, Xu Tian, Aiting Liu, Jin Huang

Journal of the National Comprehensive Cancer Network

Abstract

Durvalumab in combination with platinum/etoposide is not a cost-effective option in the first-line treatment of patients with extensive-stage SCLC.

References

	Year	Citations

Page 1